BMO Capital Markets Analysts Give Merck & Company, Inc. (MRK) a $70.00 Price Target

Merck & Company, Inc. (NYSE:MRK) received a $70.00 price objective from equities research analysts at BMO Capital Markets in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 9.75% from the stock’s current price.

Several other research firms have also recently issued reports on MRK. Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday. Credit Suisse Group reaffirmed an “outperform” rating and set a $74.00 price objective (down from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Cowen and Company reissued a “hold” rating and issued a $70.00 target price on shares of Merck & in a research report on Friday, September 1st. Jefferies Group LLC reissued a “sell” rating and issued a $52.00 target price on shares of Merck & in a research report on Sunday, August 20th. Finally, HSBC Holdings plc raised Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. Merck & presently has a consensus rating of “Hold” and an average price target of $69.69.

Shares of Merck & (MRK) traded down 1.05% during midday trading on Wednesday, reaching $63.78. The company had a trading volume of 10,096,148 shares. The company’s 50 day moving average price is $64.42 and its 200-day moving average price is $63.70. The company has a market capitalization of $173.95 billion, a P/E ratio of 34.53 and a beta of 0.80. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. During the same quarter in the prior year, the business earned $0.93 EPS. Merck &’s revenue was up .9% on a year-over-year basis. On average, equities research analysts predict that Merck & will post $3.87 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “BMO Capital Markets Analysts Give Merck & Company, Inc. (MRK) a $70.00 Price Target” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/10/11/bmo-capital-markets-analysts-give-merck-company-inc-mrk-a-70-00-price-target.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Krilogy Financial LLC increased its stake in Merck & by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after purchasing an additional 11 shares in the last quarter. HM Capital Management LLC increased its stake in Merck & by 0.4% in the 1st quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock valued at $236,000 after purchasing an additional 15 shares in the last quarter. Balentine LLC increased its stake in Merck & by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after purchasing an additional 20 shares in the last quarter. RB Capital Management LLC increased its stake in Merck & by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after purchasing an additional 23 shares in the last quarter. Finally, Baystate Wealth Management LLC increased its stake in Merck & by 0.4% in the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after purchasing an additional 27 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit